POWAY, Calif., June 17, 2026
Diazyme Laboratories, Inc. has received U.S. FDA 510(k) clearance for its Lipoprotein(a) [Lp(a)] Molarity Assay, marking an important advancement in cardiovascular diagnostics. The newly cleared assay enables clinical laboratories to quantitatively measure Lipoprotein(a) levels in human serum and plasma using molar units (nmol/L), offering a more standardized and clinically reliable approach to cardiovascular risk assessment. The regulatory milestone is expected to improve the consistency of Lp(a) testing across laboratories and support earlier identification of patients at elevated risk of cardiovascular disease.
FDA Clearance Enables Standardized Lipoprotein(a) Testing
The FDA 510(k) clearance authorizes the Diazyme Lipoprotein(a) Molarity Assay for the quantitative determination of Lp(a) concentrations in human serum and plasma. Unlike traditional mass-based assays, the new test reports results in nmol/L, a standardized molar measurement designed to minimize variability caused by differences in apolipoprotein(a) [apo(a)] isoform heterogeneity. This standardized approach improves comparability of results across different laboratories and testing platforms, addressing a long-standing challenge in the clinical interpretation of Lp(a) measurements. Consistent reporting is expected to enhance diagnostic accuracy and support evidence-based cardiovascular risk evaluation.
Isoform-Independent Assay Improves Cardiovascular Risk Assessment
According to Chong Yuan, Ph.D., Managing Director of Diazyme Laboratories, the newly cleared assay provides isoform-independent measurement of Lipoprotein(a), overcoming limitations associated with conventional testing methods. Variability in apo(a) isoform size has historically affected the accuracy and comparability of Lp(a) measurements, making risk assessment more challenging. By delivering clinically meaningful and reproducible quantification across diverse patient populations, the assay is designed to improve cardiovascular risk stratification, as elevated Lp(a) is recognized as an independent genetic risk factor for atherosclerotic cardiovascular disease. The company believes standardized testing will help clinicians identify high-risk individuals who may otherwise remain undiagnosed using older mass-based or isoform-sensitive assays.
Advertisement
Regulatory Milestone Supports Broader Clinical Adoption
The FDA clearance represents a significant milestone for Diazyme Laboratories and strengthens its portfolio of advanced diagnostic solutions for clinical laboratories. The company expects the approval to accelerate the adoption of standardized Lp(a) testing in routine cardiovascular care as healthcare providers increasingly recognize the importance of genetic lipid biomarkers in preventive medicine. By combining its proprietary enzyme and immunoassay technologies with automated chemistry analyzer compatibility, Diazyme aims to deliver high-quality diagnostic tools that improve patient management and clinical decision-making. The newly cleared assay further reinforces the growing emphasis on precision diagnostics and standardized laboratory testing in the evolving landscape of cardiovascular disease prevention.
Source: Diazyme Laboratories press release
